GO
Loading...

Sanofi SA

More

  • LOS ANGELES, Dec 23- Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year. On Monday, Express Scripts said it lined up a cheaper price for AbbVie Inc's newly...

  • LOS ANGELES, Dec 23- Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year. On Monday, Express Scripts said it lined up a cheaper price for AbbVie Inc's newly...

  • UPDATE 1-Pozen says FDA rejects lead drug again Wednesday, 17 Dec 2014 | 8:18 AM ET

    Dec 17- Pozen Inc said two versions of its experimental heart drug were rejected for the second time by the U.S. Food and Drug Administration, which again cited deficiencies in the manufacturing plant of a supplier of an active ingredient. Pozen's shares fell nearly 23 percent to $6.99 in premarket trading on Wednesday. Pozen, which first received the rejection...

  • Dec 12- Cempra Inc has no plans for now to sell itself, its CEO said, brushing off talk that the company is a potential target as big drugmakers set their sights on antibiotic developers. The deal stirred speculation that developers such as Cempra could also be takeover targets. I know a lot of other biotechs are, " Cempra Chief Executive Prabha Fernandes said in an...

  • LONDON, Dec 10- Drugmakers are finally getting more bang for their scientific buck, with the rate of return on pharmaceutical research and development increasing for the first time since 2010.. So far this year the U.S. Food and Drug Administration, which acts as gatekeeper to the world's biggest market, has approved 35 new products, up from 27 in the whole of 2013...

  • LONDON, Dec 8- Pfizer Inc is moving into the gene therapy space in the latest sign that the technology for fixing faulty genes may finally be ready for prime time, following earlier setbacks. The Spark program is expected to enter early-stage clinical trials for hemophilia B in the first half of 2015. Spark will be responsible for the early Phase I/II tests, with...

  • Ponte worked in Sanofi's Bridgewater, New Jersey, office reviewing contracts for legal compliance, according to the lawsuit. In March 2013, she discovered that nine contracts paying $34 million to accounting firm Deloitte LLP and consulting firm Accenture Plc were actually covers for kickbacks, the lawsuit said. Deloitte and Accenture are not defendants in...

  • LONDON, Dec 4- GlaxoSmithKline said on Thursday it had decided not to sell a portfolio of older drugs marketed in North America and Europe after considering offers from potential buyers. A spokesman for GSK, which was being advised on the disposal by Lazard, declined to give any more details. Bidders, who had been hoping to clinch a deal before the end of the year,...

  • Ponte worked in Sanofi's Bridgewater, New Jersey, office reviewing contracts for legal compliance, according to the lawsuit. In March 2013, she discovered that nine contracts paying $34 million to accounting firm Deloitte LLP and consulting firm Accenture Plc were actually covers for kickbacks, the lawsuit said. Deloitte and Accenture are not defendants in...

  • Lawsuit claims 'kickback' scheme at Sanofi Wednesday, 3 Dec 2014 | 3:27 PM ET
    Ousted Sanofi CEO Christopher Viehbacher

    A lawsuit accuses drug maker Sanofi and top executives, including its ousted CEO, of a million-dollar kickback scheme to promote diabetes drug sales.

  • Many posts going at North Carolina research site. LONDON, Dec 3- GlaxoSmithKline said on Wednesday it would shed "several hundred" U.S. commercial jobs and a similar number of research positions as it restructures operations in its biggest market, where drug sales are flagging. Many of the jobs lost will be from GSK's Research Triangle Park site in North Carolina...

  • GSK to ax US jobs in major cost cuts: Sources Monday, 1 Dec 2014 | 2:11 AM ET

    GSK will ax hundreds of U.S. jobs in its biggest market as the drugmaker starts implementing a major cost-saving program.

  • LONDON, Nov 30- GlaxoSmithKline will this week inform U.S. staff of hundreds of job cuts in its biggest market as the drugmaker starts implementing a major cost-saving programme, sources familiar with the matter said on Sunday. Britain's top drugmaker announced at third-quarter results on Oct. 22 that the new restructuring scheme would save 1 billion pounds in...

  • Pfizer deal would probably have failed: AZ CEO Friday, 28 Nov 2014 | 1:01 AM ET
    Viagra made by Pfizer and Nexium made by AstraZeneca.

    Pfizer's attempt to take over AstraZeneca through a $110 billion bid would have run aground on changes to U.S. tax laws, even if the companies had reached a deal.

  • *Developed by UniQure and marketed in Europe by Chiesi. FRANKFURT/ LONDON, Nov 26- The Western world's first gene therapy drug is set to go on sale in Germany with a 1.1 million euro price tag, a new record for a medicine to treat a rare disease. The sky-high cost of Glybera, from Dutch biotech firm UniQure and its unlisted Italian marketing partner Chiesi, shows how...

  • Fighting kids' cancer, one voucher at a time Friday, 21 Nov 2014 | 10:03 AM ET
    Jacob with his parents Mike Froman and Nancy Goodman, and brother Ben (Spring 2008)

    There are few new cancer drugs to treat kids, and not much research is being done.

  • Europe closes down after PMI miss, Sanofi struggles Thursday, 20 Nov 2014 | 4:30 PM ET

    European shares closed lower on Thursday as investors reacted to worse-than-expected data from the euro zone.

  • Nov 20- Global pharmaceutical spending will break the trillion dollar mark in 2014, driven by high prices in the United States for novel treatments such as Gilead Sciences Inc's Sovaldi for hepatitis C and new cancer drugs, according to a study released on Thursday. Total spending on drugs will hit $1.06 trillion, an increase of 7 percent over 2013 levels,...

  • Sanofi's case for experimental drugs in pipeline Wednesday, 19 Nov 2014 | 12:24 PM ET

    After drug company Sanofi removed CEO Chris Viehbacher, investors question the future of the company's growth and future.

  • CHICAGO, Nov 17- Regeneron Corp's experimental drug alirocumab helped 10 times as many high-risk patients unable to tolerate widely-used statins get their "bad" LDL cholesterol down to target levels than Merck& Co's Zetia, according to data from a clinical trial presented on Monday. Alirocumab, developed along with French drugmaker Sanofi, belongs to a new...